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Aims To describe the cardiac abnormalities in patients with COVID-19 and identify the characteristics of patients who
would benefit most from echocardiography.
...................................................................................................................................................................................................
Methods
and results
In a prospective international survey, we captured echocardiography findings in patients with presumed or
confirmed COVID-19 between 3 and 20 April 2020. Patient characteristics, indications, findings, and impact
of echocardiography on management were recorded. Multivariable logistic regression identified predictors of
echocardiographic abnormalities. A total of 1216 patients [62 (52–71) years, 70% male] from 69 countries
across six continents were included. Overall, 667 (55%) patients had an abnormal echocardiogram. Left and right
ventricular abnormalities were reported in 479 (39%) and 397 (33%) patients, respectively, with evidence of new
myocardial infarction in 36 (3%), myocarditis in 35 (3%), and takotsubo cardiomyopathy in 19 (2%). Severe cardiac
disease (severe ventricular dysfunction or tamponade) was observed in 182 (15%) patients. In those without
pre-existing cardiac disease (n = 901), the echocardiogram was abnormal in 46%, and 13% had severe disease.
Independent predictors of left and right ventricular abnormalities were distinct, including elevated natriuretic pepti-
des [adjusted odds ratio (OR) 2.96, 95% confidence interval (CI) 1.75–5.05) and cardiac troponin (OR 1.69, 95%
CI 1.13–2.53) for the former, and severity of COVID-19 symptoms (OR 3.19, 95% CI 1.73–6.10) for the latter.
Echocardiography changed management in 33% of patients.
...................................................................................................................................................................................................
Conclusion In this global survey, cardiac abnormalities were observed in half of all COVID-19 patients undergoing echocardiog-
raphy. Abnormalities were often unheralded or severe, and imaging changed management in one-third of patients.
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Introduction
Coronavirus disease 2019 (COVID-19) has emerged as a major
cause of morbidity and mortality that is placing unprecedented pres-
sure on healthcare services across the world.1,2 Whilst the severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) respon-
sible for COVID-19 predominantly affects the respiratory tract,3
patients with cardiovascular risk factors or established disease4 and
those with elevated cardiac biomarkers appear to be more suscep-
tible and to have a worse prognosis.5,6 The mechanisms underlying
these initial observations remain unclear.
Early case reports suggest that COVID-19 can cause a wide range
of cardiac conditions that include acute myocardial infarction,7 myo-
carditis,8 and takotsubo cardiomyopathy.9 Acute left and right ven-
tricular failure may be a direct consequence of cardiac pathology,
with the latter also arising secondary to elevations in right ventricular
afterload due to pulmonary embolism or pneumonia.10 Virus par-
ticles have been observed in the myocardium and vascular endothe-
lium in patients with COVID-19 and cardiogenic shock.11,12
However, the incidence of these cardiac complications and the sub-
sequent implications for treatment and resource allocation are un-
known. Consequently, there is an urgent need to better understand
the interactions between COVID-19 and the heart.
Echocardiography is well placed to help further this understanding,
being inexpensive, portable, and widely accessible. However, a large
systematic evaluation of echocardiography in all patients with
COVID-19 would be highly challenging due to the logistical consider-
ations of testing, consumption of personal protective equipment
(PPE), and the risk of further viral transmission. We therefore con-
ducted a global survey to capture the findings of echocardiography
performed on clinical grounds in patients with confirmed or a high
probability of COVID-19. We aim to improve our understanding of
the cardiac manifestations of COVID-19, and to provide insights into
the characteristics of patients who would benefit most from
echocardiography.
Methods
This global online survey of echocardiography in patients with COVID-19
was designed by the European Association of Cardiovascular Imaging
(EACVI), with input from external international experts.13 Any trans-
thoracic echocardiogram that was performed on a patient with con-
firmed, or a high probability of, COVID-19 in the hospital setting was
eligible for inclusion. Patients were imaged as part of routine care, and
non-identifiable patient data were captured. As such, this audit did not re-
quire individual patient consent and this approach was approved by the
European Society of Cardiology and by local research ethics committees.
An online format was developed (https://www.surveymonkey.com/r/
2FBFFQD) that allows rapid completion of 11 questions on a smartphone
by sonographers or clinicians immediately after completion of the echo-
cardiogram. For most questions, the operator selects from several pre-
specified answers, with the option to select multiple answers and to pro-
vide free-text comments (Supplementary material online, Appendix). First,
several baseline characteristics are recorded: age, sex, comorbidities,
symptom severity, COVID-19 status, presence of pneumonia, and the lo-
cation in hospital where imaging was performed. Secondly, the indication
for imaging is recorded: suspected left heart failure, suspected right heart
failure, chest pain with ST-segment elevation on the electrocardiogram,
cardiac biomarker elevation [troponin or brain natriuretic peptide
(BNP)], ventricular arrhythmia, suspected tamponade, or cardiogenic
shock. Thirdly, echocardiographic findings are captured for left ventricu-
lar abnormalities (normal, mild, moderate, or severe systolic dysfunction,
dilatation, evidence of new myocardial infarction, myocarditis, or takot-
subo cardiomyopathy), right ventricular abnormalities (normal, mild or
moderate, or severe systolic dysfunction, dilatation, D-shaped left ven-
tricle, or elevated pulmonary artery pressure), or cardiac tamponade.
The survey then captures whether the echocardiogram changed patient
management.
This prospective survey (www.escardio.org/eacvi/surveys) was distrib-
uted to the EACVI network and its wider membership,14,15 to a pre-
established European Society of Cardiology database of cardiologists
with an interest in cardiac imaging, and to the presidents and chairpersons
of national societies and working groups in imaging across the world. It
was also distributed widely on social media platforms.
Statistical analysis
Survey entries were excluded if there were incompatible, incom-
plete, or conflicting data, or if there were no echocardiographic find-
ings recorded. In this analysis, missing values were not imputed. Age
was reported as median with an interquartile interval, and categorical
variables were reported as frequencies (%). Between-group compari-
sons were performed using the v2 test or an independent samples t-
test. In the primary analysis, patients with either confirmed or prob-
able COVID-19 were included. A sensitivity analysis was performed
restricted to those with confirmed COVID-19. A critical care setting
was defined as intensive care, high dependency, or coronary care
units, the emergency department, or the cardiac catheterization la-
boratory. A normal echocardiogram was defined as normal left and
right ventricular function, with no other reported abnormalities. To
evaluate associations between clinical variables and cardiac abnor-
malities that were more likely to be due to COVID-19, an analysis
was performed in patients without pre-existing cardiac disease, after
excluding those with previous ischaemic heart disease, heart failure,
or valvular heart disease. Univariable and multivariable logistic regres-
sion models were constructed separately with an abnormal left ven-
tricle (any degree of left ventricular dysfunction or dilatation,
myocardial infarction, myocarditis, or takotsubo cardiomyopathy) or
abnormal right ventricle (any right ventricular dysfunction or dilata-
tion, a D-shaped left ventricle, or pulmonary hypertension) as the de-
pendent variables. Covariates included age, gender, scan location,
symptom severity, hypertension and diabetes mellitus, and the indica-
tion for echocardiography. Analysis was performed using R version
3.5.0 (R Foundation for Statistical Computing, Vienna, Austria).
Results
The survey was launched on 3 April 2020. The results reported here
comprise data from the first 17 days of the survey, with the last date
of collection on 20 April 2020. Data from 1272 patients undergoing
echocardiography were collected from 69 countries across six conti-
nents where COVID-19 has been reported (Figure 1). Data were
available for analysis in 1216 (96%) patients [62 (52–71) years, 70%
male], of whom 813 (73%) had confirmed COVID-19, and 298 (27%)
had a high probability at the time of scanning (Table 1).
2 M. R. Dweck et al.
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..Overall, 60% of scans were performed in a critical care setting
(54% intensive care, 2% high dependency unit and coronary care unit,
5% emergency room, and 1% cardiac catheter laboratory), with the
remainder performed in general medicine, cardiology, respiratory,
and dedicated COVID-19 wards (Table 1). Correspondingly, 54% of
patients had severe symptoms and 19% had evidence of pneumonia.
Pre-existing cardiac disease was reported in 26% of patients due to a
combination of ischaemic heart disease (14%), heart failure (9%), or
valvular heart disease (7%). Hypertension (37%) and diabetes mellitus
(19%) were also common. The most common indications for echo-
cardiography were suspected left-sided heart failure (40%), elevated
cardiac biomarkers (26%), and right-sided heart failure (20%). Chest
pain with ST-segment elevation on the electrocardiogram (9%), cir-
culatory shock (8%), ventricular arrhythmia (3%), and suspected
cardiac tamponade (2%) were less frequent, as were other indica-
tions, such as suspected pulmonary embolism (5%), endocarditis
(6%), and myocarditis (1%).
Echocardiographic findings
Compared with patients with a normal echocardiogram (n = 549,
45%), patients with an abnormal scan (n = 667, 55%) were
older and had a higher prevalence of pre-existing ischaemic heart
disease, heart failure, or valvular heart disease, but a similar
prevalence of hypertension or diabetes mellitus. The proportion
of males was similar in both groups (Table 1; Figure 2, Central
Illustration).
Figure 1 Prevalence of COVID-19 and countries contributing to the global online survey of echocardiography. (A) The prevalence of COVID-19
on 20 April for the 185 countries for which data were available through the Johns Hopkins Center for Systems Science and Engineering COVID-19
dashboard.25 (B) The location and number of scans reported in the global online survey of echocardiography during a 17-day period from 3 to 20
April 2020.
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patients, with echocardiographic evidence of new myocardial infarc-
tion in 36 (3%), myocarditis in 35 (3%), and takotsubo cardiomyop-
athy in 19 (2%). Left ventricular impairment was classified as mild,
moderate, or severe in 17, 12, and 9% of patients, respectively. Right
ventricular abnormalities were reported in 397 (33%) patients, with
mild or moderate right ventricular impairment in 19% and severe im-
pairment in 6%. Right ventricular dilatation (15%), elevated
pulmonary artery pressures (8%), and a D-shaped left ventricle (4%)
were reported less frequently. Cardiac tamponade and endocarditis
were reported in 11 (1%) and 14 (1%) patients, respectively. Severe
cardiac disease, defined as severe left or right ventricular dysfunction
or cardiac tamponade, was reported in 1 in 7 patients (n = 182, 15%;
Supplementary material online, Table S1).
Abnormalities on the echocardiogram were more common in
those where the indication for imaging was chest pain with ST-
....................................................................................................................................................................................................................
Table 1 Patient characteristics and indications for echocardiography
Overall (n5 1216) Abnormal scan (n5 667) Normal scan (n5 549) P-value*
Age 62 (52–71) 64 (53–73) 60 (51–69) <0.001
Sex 0.600
Female 365 (30%) 195 (29%) 170 (31%)
Male 844 (70%) 468 (71%) 376 (69%)
Location of scan 0.053
Critical care 726 (60%) 382 (57%) 344 (63%)
Non-critical care 486 (40%) 284 (43%) 202 (37%)
COVID-19 status <0.001
Confirmed 813 (73%) 409 (68%) 404 (79%)
High probability 298 (27%) 193 (32%) 105 (21%)
Evidence of pneumonia 232 (19%) 135 (20%) 97 (18%) 0.300
Symptom severity <0.001
Mild 215 (18%) 98 (15%) 117 (23%)
Moderate 327 (28%) 210 (32%) 117 (23%)
Severe 625 (54%) 340 (52%) 285 (55%)
Co-morbidities
Hypertension 445 (37%) 254 (38%) 191 (35%) 0.300
Diabetes mellitus 233 (19%) 136 (20%) 97 (18%) 0.300
Ischaemic heart disease 167 (14%) 137 (21%) 30 (6%) <0.001
Heart failure 113 (9%) 106 (16%) 7 (1%) <0.001
Valvular heart disease 80 (7%) 53 (8%) 27 (5%) 0.045
Indication
Suspected left heart failure 491 (40%) 294 (44%) 197 (36%) 0.011
Suspected right heart failure 243 (20%) 145 (22%) 98 (18%) 0.200
Chest pain and ST-elevation 107 (9%) 76 (11%) 31 (6%) 0.001
Elevated cardiac biomarkers 314 (26%) 216 (32%) 98 (18%) <0.001
Troponin 239 (20%) 164 (25%) 75 (14%) <0.001
BNP 129 (11%) 97 (15%) 32 (6%) <0.001
Ventricular arrhythmia 38 (3%) 33 (5%) 5 (1%) <0.001
Cardiac tamponade 20 (2%) 13 (2%) 7 (1%) 0.600
Circulatory shock 95 (8%) 65 (20%) 30 (6%) 0.017
Change in management <0.001
Yes 405 (33%) 297 (45%) 108 (20%)
No 675 (56%) 309 (46%) 366 (67%)
Not known 136 (11%) 61 (9%) 75 (14%)
Management group <0.001
Disease-specific therapy 171 (14%) 130 (19%) 41 (8%)
Level of care 32 (3%) 20 (3%) 12 (2%)
Haemodynamic support 51 (4%) 35 (5%) 16 (3%)
Other 151 (12%) 112 (17%) 39 (7%)
Median (interquartile range), number (%). Abbreviations: BNP, brain B-type natriuretic peptide; COVID-19, coronavirus disease 2019.
*Between-group comparisons are v2 test or independent samples t-tests
Missing values in the overall population: age = 18; sex = 7; location of scan = 4; COVID-19 status = 8; symptom severity = 49; indication = 9.
4 M. R. Dweck et al.
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segment elevation (71%), elevated biomarkers (69%), suspected left
ventricular failure (60%), suspected right ventricular failure (60%), or
where multiple indications were present (72%) (Table 2; Figure 3). In a
sensitivity analysis restricted to the 813 patients with confirmed
COVID-19, the proportion with an abnormal echocardiogram was
similar to the overall population at 50% (409/813), and 1 in 7 patients
had severe cardiac disease (n = 119, 15%).
Patients without pre-existing
cardiac disease
After excluding 315 patients with pre-existing ischaemic heart dis-
ease, heart failure, or valvular heart disease, 901 patients were identi-
fied [60 (50–69) years, 68% male] (Supplementary material online,
Table S2). These patients were more likely to have a normal echocar-
diogram (54%, 488/901) than those with pre-existing heart disease
(19%, 61/315; P < 0.001). Suspected left ventricular failure was the
most common indication for scanning (35%), followed by suspected
right heart failure (23%) and elevated cardiac biomarker concentra-
tion (23%). A quarter of patients had an abnormal left ventricle and a
third had an abnormal right ventricle. On both univariable and multi-
variable analysis, the covariates and indications for echocardiography
that predicted an abnormal left and right ventricle differed (Figure 4;
Supplementary material online, Tables S3 and S4). The independent
predictors of an abnormal left ventricle were suspected left heart fail-
ure [odds ratio (OR) 1.63, 95% confidence interval (CI) 1.15–2.32],
chest pain with ST-segment elevation (OR 4.08, 95% CI 2.40–6.99),
troponin elevation (OR 1.69, 95% CI 1.13–2.53), and BNP elevation
(OR 2.96, 95% CI 1.75–5.05). In contrast, the independent predictors
of an abnormal right ventricle were suspected right heart failure (OR
2.65, 95% CI 1.88–3.75) and moderate (OR 2.34, 95% CI 1.32–4.29)
or severe COVID-19 symptoms (OR 3.19, 95% CI 1.73–6.10).
Overall, 1 in 8 of these patients without pre-existing cardiac disease
(13%) had severe cardiac disease identified on echocardiography.
Changes in management
In 405 (33%) patients, an immediate change in management due to
the echocardiogram was reported (Table 1). In the remaining 811
(67%) patients, no change in management was reported in 675
(56%), or it was not clear to the echocardiographer whether there
had been a change in management in 136 (11%), as the individuals
performing the scan were not directly involved in guiding the patients’
care. An immediate change in management occurred more often in
those patients with an abnormal compared with a normal echocar-
diogram (45% vs. 20%, P < 0.001, Figure 3) and similarly in those with
severe disease compared with those with no severe disease identified
on echocardiogram (59% vs. 29%, P < 0.001; Supplementary material
online, Table S1). Specific changes in management reported in the
free-text comments were collated into four groups. In patients in
whom a change in management was reported, the echocardiogram
led to changes in disease-specific therapy in 42% (171/405), such as
initiating therapy for heart failure, acute coronary syndrome, tampon-
ade, or pulmonary embolism, and commencing antimicrobial therapy
for endocarditis. The echocardiogram also facilitated decisions
regarding changes in the level of patient care in 8% (32/405), and
guided titration of haemodynamic support in 13% (51/405). In the
remaining 37% (151/405) where management changed, the change
was not described. Changes in management were reported in a
higher proportion of patients with pre-existing cardiac disease com-
pared with those without (38% vs. 32%, P = 0.005), and in those with
elevated cardiac biomarkers compared with the remaining popula-
tion (39% vs. 31%, P < 0.001).
Discussion
We report findings from the first international survey of echocardiog-
raphy in patients with confirmed or suspected COVID-19. Data from
1216 patients scanned in 69 countries across six continents demon-
strated left or right ventricular abnormalities in half of all patients
with COVID-19 undergoing echocardiography, and that these abnor-
malities were severe in 1 in 7 patients. The majority had non-specific
patterns of ventricular dysfunction, although new myocardial infarc-
tion, myocarditis, and takotsubo cardiomyopathy were observed in a
minority of patients. Echocardiography was reported to directly
change patient management in a third of cases including alterations to
disease-specific management, haemodynamic support, and the level
of care received by the patients.
The simple online format of this survey allowed rapid capture of
the echocardiographic findings from a large number of patients with
Figure 2 Central Illustration. Mosaic plot illustrating the findings
on echocardiography in patients with COVID-19.
Mosaic plot illustrating the distribution of normal and abnormal echocar-
diogram findings in patients with suspected or confirmed COVID-19 infec-
tion. Box size is proportional to the number of patients per category. Left
ventricular abnormalities are shown in orange and right ventricular
abnormalities are shown in blue, both in the independent boxes and in
the biventricular failure box. Survey respondents could enter data for
multiple categories of left or right ventricular abnormality, therefore sub-
categories are not mutually exclusive. Eleven patients had evidence of
cardiac tamponade which was an isolated finding in three patients, illus-
trated in purple. LV, left ventricle; MI, myocardial infarction; PAP, pulmon-
ary arterial pressure.
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COVID-19 during the pandemic’s peak. This was facilitated by our
ability to disseminate and to publicize the survey via social media and
through an established global network of imaging specialists. This for-
mat allowed us to keep pace with the rapid spread of COVID-19
around the world. Most scans were performed in the current epi-
centres of the outbreak: the UK, Italy, Spain, France, and the USA.
While undoubtedly a global survey, our data remain representative
of the current geographical distribution of the virus.
Whilst our previous understanding of how COVID-19 affects the
heart was limited to case reports and case series,7–9 consistent epi-
demiological data have demonstrated that patients with established
cardiovascular disease, risk factors, or elevated cardiac biomarkers
have an increased susceptibility to infection and an increased risk of
severe disease and death.3–6 Severe cardiac disease was observed in
1 in 7 patients across the whole cohort and in 1 in 8 patients without
pre-existing cardiac disease. This proportion rose to 1 in 5 when the
indication for imaging included raised cardiac biomarkers. The pro-
portion of abnormal echocardiograms and those demonstrating se-
vere cardiac disease were similar after excluding patients with
previously established cardiac disease (heart failure, valve disease, or
ischaemic heart disease), suggesting that in this population the cardiac
abnormalities relate to COVID-19 infection.
The pattern of cardiac injury observed in our survey appears to be
consistent with the cardiovascular involvement observed in patients
with other severe viral respiratory infections.16–19 Right ventricular
abnormalities were observed in a quarter of patients and were more
common in patients with more severe symptoms of COVID-19.
These are likely to reflect severe respiratory disease, including the
viral pneumonia itself, as well as both clinical and subclinical pulmon-
ary thrombo-embolism.20 Left ventricular abnormalities were pre-
sent in a third of patients and were predominantly non-specific in
nature. Further research is required to define the mechanism of this
dysfunction as only occasionally were echocardiographic patterns
consistent with myocardial infarction, myocarditis, or takotsubo car-
diomyopathy. The latter conditions are often difficult to recognize
during an isolated echocardiogram, particularly when performed in a
critical care setting, and, as such, their true prevalence may have been
underestimated.
In a third of patients who underwent echocardiography on clinical
indication, imaging was reported to result in an immediate change in
patient management. This included changes in disease-specific thera-
pies, such as pericardiocentesis or therapy for heart failure, pulmon-
ary embolism, or acute coronary syndromes. It also contributed to
decisions regarding the level of patient care, such as the admission of
patients to critical care, and the need for titration of haemodynamic
support. In practice, this proportion may have been underestimated
as echocardiographers may not have fully appreciated the conse-
quences of their scan at the time of imaging. In addition, a majority of
Figure 3 Alluvial plot illustrating the indications for echocardiography and impact on patient management grouped according to the scan findings.
Colours represent findings reported on echocardiography. All patients for whom complete data were available for indication, findings, and change in manage-
ment were included in this plot [89% (1080/1216)]. The elevated biomarker indication subgroup includes both indication for raised troponin and indication for ele-
vated BNP. Changes in management (impact) include those where changes in disease-specific therapy, titration of haemodynamic support, or changes in the
level of patient care were described.
6 M. R. Dweck et al.
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Table 2 Echocardiographic findings stratified by indication
Overall*†
(n5 1216)
Suspected
left heart
failure
(n5 491)
Suspected
right heart
failure
(n5 243)
Chest pain
and ST
elevation
(n5 107)
Elevated
cardiac
biomarkers
(n5 314)
Elevated
troponin
(n5 239)
Elevated
BNP
(n5 129)
Multiple
indications
(n5 276)
Other‡
(n5 299)
Overall findings
Normal
echocardiogram
549 (44%) 197 (40%) 98 (40%) 31 (29%) 98 (31%) 75 (31%) 32 (25%) 76 (28%) 180 (60%)
Abnormal
echocardiogram
667 (53%) 294 (60%) 145 (60%) 76 (71%) 216 (69%) 164 (69%) 97 (75%) 200 (72%) 119 (40%)
Severe cardiac
disease§
182 (15%) 81 (16%) 40 (16%) 11 (10%) 62 (20%) 44 (18%) 33 (26%) 63 (23%) 40 (13%)
Left ventricle*
Normal 745 (61%) 247 (50%) 186 (77%) 33 (31%) 139 (44%) 109 (46%) 45 (35%) 114 (41%) 223 (75%)
Mild impairment 203 (17%) 92 (19%) 33 (14%) 38 (36%) 74 (24%) 60 (25%) 32 (25%) 66 (24%) 33 (11%)
Moderate
impairment
140 (12%) 81 (16%) 10 (4%) 22 (21%) 50 (16%) 32 (13%) 25 (19%) 41 (15%) 18 (6%)
Severe impairment 112 (9%) 66 (13%) 12 (5%) 9 (8%) 45 (14%) 32 (13%) 26 (20%) 49 (18%) 21 (7%)
Dilated 66 (5%) 40 (8%) 8 (3%) 7 (7%) 31 (10%) 22 (9%) 19 (15%) 31 (11%) 11 (4%)
Evidence of new MI 36 (3%) 13 (3%) 4 (2%) 14 (13%) 22 (7%) 22 (9%) 7 (5%) 19 (7%) 4 (1%)
Evidence of
myocarditis
35 (3%) 21 (4%) 4 (2%) 8 (8%) 24 (8%) 19 (8%) 13 (10%) 24 (9%) 4 (1%)
Evidence of
takotsubo
19 (2%) 5 (1%) 1 (1%) 4 (4%) 11 (4%) 10 (4%) 5 (4%) 8 (3%) 6 (2%)
Right ventricle*
Normal 842 (69%) 335 (68%) 124 (51%) 79 (74%) 206 (66%) 158 (66%) 79 (61%) 163 (59%) 224 (75%)
Mild to moderate
impairment
236 (19%) 100 (20%) 64 (26%) 23 (21%) 79 (25%) 61 (26%) 37 (29%) 79 (29%) 48 (16%)
Severe impairment 77 (6%) 27 (6%) 32 (13%) 4 (4%) 20 (6%) 14 (6%) 9 (7.0%) 22 (8%) 16 (5%)
Dilated 181 (15%) 56 (11%) 76 (31%) 5 (5%) 44 (14%) 33 (14%) 21 (16%) 48 (17%) 41 (14%)
D-shaped left ventricle 46 (4%) 10 (2%) 22 (9%) 0 (0%) 8 (3%) 5 (2%) 6 (5%) 8 (3%) 12 (4%)
Elevated PAP 99 (8%) 31 (6%) 46 (19%) 3 (3%) 33 (11%) 23 (10%) 15 (12%) 31 (11%) 18(6%)
Other
Tamponade 11 (1%) 3 (1%) 1 (1%) 0 (0%) 2 (1%) 2 (1%) 1 (1%) 3 (1%) 6 (2%)
Endocarditis 14 (1%) 3 (1%) 1 (1%) 0 (0%) 2 (1%) 1 (1%) 1 (1%) 2 (1%) 11 (4%)
Change in management
Yes 405 (33%) 169 (34%) 85 (35%) 41 (38%) 123 (39%) 96 (40%) 53 (41%) 119 (43%) 96 (32%)
No 675 (56%) 243 (49%) 118 (49%) 62 (58%) 178 (57%) 133 (56%) 73 (57%) 134 (49%) 182 (61%)
Not known 136 (11%) 79 (16%) 40 (16%) 4 (4%) 13 (4%) 10 (4%) 3 (2%) 23 (8%) 21 (7%)
Management group
Disease-specific
therapy
171 (14%) 63 (13%) 38 (16%) 16 (15%) 53 (17%) 39 (16%) 26 (20%) 47 (17%) 42 (14%)
Level of care 32 (3%) 9 (2%) 3 (1%) 3 (3%) 6 (2%) 6 (3%) 1 (1%) 4 (1%) 13 (4%)
Haemodynamic
support
51 (4%) 21 (4%) 11 (5%) 4 (4%) 12 (4%) 10 (4%) 3 (2%) 16 (6%) 14 (5%)
Other 151 (12%) 76 (15%) 33 (14%) 18 (17%) 52 (17%) 41 (17%) 23 (18%) 52 (19%) 27 (9%)
Values are number (%). BNP, brain natriuretic peptide; PAP, pulmonary artery pressure; LV, left ventricle; MI, myocardial infarction; RV, right ventricle.
*Groups are not mutually exclusive as patients may have more than one indication for echocardiography or abnormality.
†Nine patients included in the analysis had missing indications.
‡The other group includes patients with indication of ventricular arrhythmia, tamponade, circulatory shock, and a combination of free-text indications such as suspected endo-
carditis, or pulmonary embolus.
§Severe cardiac disease is defined as severe left ventricular or right ventricular dysfunction or cardiac tamponade.
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patients had echocardiography performed in an intensive care unit. In
this setting, optimization of management may have been previously
instituted or changes in management limited by severe respiratory or
haemodynamic compromise. Few previous studies have reported
the impact of echocardiography on changes in management, and
none has been performed in a critical care setting.21 To put our find-
ings into context, Bethge et al. report in an outpatient setting that
whilst 22% of patients had abnormal findings, management changed
in only 3% of patients.22 Finally, we suggest that information support-
ing the continuation of a management strategy may be as clinically
relevant as information that leads to the initiation of an alternative
strategy.
The complex logistics involved in performing echocardiography in
patients with COVID-19 and the risk of virus transmission necessi-
tates robust selection of patients for imaging.23 Our data do not imply
that all patients with COVID-19 require an echocardiogram. Indeed,
patients undergoing echocardiography here had clearly defined clinic-
al indications. Our data suggest that cardiac biomarkers may help im-
prove the selection of patients for imaging, with elevated BNP and
cardiac troponin concentrations independent predictors of left and
right ventricular abnormalities, respectively. Building on this study,
there is now a need for future imaging and biomarker studies to sys-
tematically investigate the cardiovascular manifestations of COVID-
19, and to establish their true prevalence. The CAPACITY-COVID
European Registry aims to determine the role of cardiovascular dis-
ease in the COVID-19 pandemic through standardized large-scale
data collection.24 Imaging with echocardiography and cardiovascular
magnetic resonance following recovery from COVID-19 will be
more readily achievable and will be well placed to define any residual
cardiac damage caused by the condition. Similarly, studies investigat-
ing whether cardiac biomarkers can better direct clinical imaging and
improve patient outcomes would be welcome.
Our study suffers from the usual limitations associated with an ob-
servational survey. Whilst by design we sought to conduct a rapid
survey capturing key echocardiographic findings during the pandem-
ic’s peak, this limited the amount and granularity of the data we could
capture. We are reliant on operator-reported findings, as is common
in clinical practice, and acknowledge that definitive assessment and
core lab verification of cardiac function with echocardiography in crit-
ically ill patients is challenging. A proportion of the data was collected
from free text-fields, and as such may be biased and represent an
underestimate of these findings or clinical variables. Additionally, this
Figure 4 Predictors of an abnormal left (red) and right (blue) ventricle on echocardiography in patients with COVID-19 without pre-existing car-
diac disease.
Two multivariable logistic regression models examined the associations of clinical covariates with abnormal left ventricular or abnormal right ventricular findings
on echocardiography. Categorical covariate data comprised only those answers that were pre-defined in survey questions and were selected a priori based on
clinical relevance. *Those with mild symptoms were the referent group for symptom severity. BNP, brain type natriuretic peptide.
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..survey is subject to substantial case selection bias. For example, we do
not know the prevalence of abnormalities in those who did not under-
go scanning. In view of the complex logistics around scanning, echocar-
diography was probably limited to those with clear clinical indications
or those with increased disease severity. Furthermore, the use of echo-
cardiography has probably decreased in the current pandemic due to
concerns over viral transmission, and this may further contribute to the
selection of patients for scanning. We did not capture patient out-
comes, but many of the relevant outcomes have yet to occur. Finally,
there were relatively few data from certain countries, including China.
As the survey continues, we will seek to better target and gather more
information from these countries, with further reports to follow.
In this global survey, cardiac abnormalities were observed in half of
all COVID-19 patients undergoing echocardiography. Abnormalities
were often unheralded or severe, and imaging changed management
in one-third of patients.
Supplementary material
Supplementary material is available at European Heart Journal –
Cardiovascular Imaging online.
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